Celltrion Pharm Inc.
068760 | KO
Overview
Corporate Details
- ISIN(s):
- KR7068760008
- LEI:
- Country:
- South Korea
- Address:
- 충청북도 청주시 청원구 오창읍 2산단로 82셀트리온제약, 청주시
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-29 00:00 |
Governance Information
대규모기업집단현황공시[분기별공시(개별회사용)]
|
Korean | 8.9 KB | ||
| 2025-08-14 00:00 |
Regulatory Filings
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
|
Korean | 11.1 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 2.6 MB | ||
| 2025-06-23 00:00 |
Major Shareholding Notification
[기재정정]대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
|
Korean | 135.3 KB | ||
| 2025-05-30 00:00 |
Major Shareholding Notification
대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
|
Korean | 100.8 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.4 MB | ||
| 2025-05-07 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 25.8 KB | ||
| 2025-04-10 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.9 KB | ||
| 2025-04-10 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 252.0 KB | ||
| 2025-04-04 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-04-04 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-04-04 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-04-04 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.9 KB | ||
| 2025-04-04 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-04-04 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB |
Automate Your Workflow. Get a real-time feed of all Celltrion Pharm Inc. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Celltrion Pharm Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Celltrion Pharm Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America
950130
United States of America
950130
Developing cytisinicline, a plant-based treatment for smoking cessation and nicotine addiction.
United States of America
ACHV
United States of America
ACHV
Developing precision medicine to diagnose, treat, and prevent neurodegenerative diseases.
United States of America
ACIU
United States of America
ACIU
A clinical-stage biopharma developing novel drugs for immuno-inflammatory diseases.
United States of America
ACRS
United States of America
ACRS
Develops precision cancer therapies by matching patients to drugs using its proteomics platform.
United States of America
ACRV
United States of America
ACRV
Clinical-stage biopharma developing a first-in-class drug for thrombotic diseases like stroke.
France
ALACT
France
ALACT
Develops targeted radiotherapies for advanced cancers like AML and prostate cancer.
United States of America
ATNM
United States of America
ATNM
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America
ACTU
United States of America
ACTU
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden
ACUC
Sweden
ACUC
Clinical-stage biopharma developing an antibody therapy for Alzheimer's by targeting toxic AβOs.
United States of America
ABOS
United States of America
ABOS